COV Stock Analysis: Covivio | PA

REIT - Diversified | PA, France | Market Cap: 6.109m EUR | 12M Return: 1.2% | Charts, Fundamentals & Technical Analysis

Offices, Hotels, Residential, Urban Development
Total Rating 36
Safety 56
Buy Signal -0.67
REIT - Diversified
Industry Rotation: -4.5
Market Cap: 6.97B
Avg Turnover: 6.53M
Risk 3d forecast
Volatility23.3%
VaR 5th Pctl3.98%
VaR vs Median3.71%
Reward TTM
Sharpe Ratio0.14
Rel. Str. IBD22.3
Rel. Str. Peer Group10
Character TTM
Beta0.172
Beta Downside-0.036
Hurst Exponent0.593
Drawdowns 3y
Max DD21.91%
CAGR/Max DD0.48
CAGR/Mean DD1.47

Warnings

Altman Z'' In Financial Distress Zone
Choppy

Tailwinds

Confidence

Seasonality 10.5 years of data

Jan -0.8% 4
Feb -1.7% 33
Mar -0.5% 3
Apr +3.3% 34
May +1.1% 44
Jun -3.3% 28
Jul +4.0% 31
Aug +0.9% 14
Sep -0.8% 9
Oct -2.2% 27
Nov -1.3% 15
Dec +0.4% 4

Average return per month, with how dependable it is below — did the month move the same way every year (high) or randomly (low). Above 60 is a pattern worth trusting; under 40 is noise.

Description: COV Covivio

Covivio SA is a French real estate company operating at a European scale, focused on combining working, traveling, and living spaces by engaging closely with end users. The company manages €23.7 billion in assets and serves businesses, hotel operators, and territorial authorities, supporting their needs around attractiveness, transformation, and responsible performance. Incorporated in 1963 and listed on Euronext Paris (COV), Covivio operates as a diversified REIT, meaning it generates income from multiple property types including offices, residential, and hospitality assets rather than concentrating on a single segment. The company emphasizes a stakeholder-oriented business model, positioning real estate as a driver of well-being and long-term urban value creation.

Headlines to Watch Out For
  • ECB rate cuts ease refinancing pressure on portfolio debt
  • Office occupancy recovery in Paris and Milan lifts rental income
  • German residential rent caps constrain revenue growth
Piotroski VR-10 (Strict) 2.5
Net Income: 738.7m TTM > 0 and > 6% of Revenue
FCF/TA: 0.01 > 0.02 and ΔFCF/TA -0.84 > 1.0
NWC/Revenue: -64.71% < 20% (prev -7.07%; Δ -57.65% < -1%)
CFO/TA 0.03 > 3% & CFO 708.3m > Net Income 738.7m
Net Debt (10.0b) to EBITDA (1.45b): 6.93 < 3
Current Ratio: 0.64 > 1.5 & < 3
Outstanding Shares: last quarter (110.8m) vs 12m ago 10.65% < -2%
Gross Margin: 41.67% > 18% (prev 62.87%; Δ -21.19% > 0.5%)
Asset Turnover: 4.23% > 50% (prev 4.50%; Δ -0.26% > 0%)
Interest Coverage Ratio: 3.85 > 6 (EBIT TTM 1.30b / Interest Expense TTM 338.1m)
Altman Z'' 0.98
A: -0.03 (Total Current Assets 1.21b - Total Current Liabilities 1.90b) / Total Assets 25.3b
B: 0.03 (Retained Earnings 738.7m / Total Assets 25.3b)
C: 0.05 (EBIT TTM 1.30b / Avg Total Assets 25.1b)
D: 0.68 (Book Value of Equity 8.61b / Total Liabilities 12.7b)
Altman-Z'' = 0.98 = BB
Beneish M -2.64
DSRI: 0.91 (Receivables 330.5m/382.0m, Revenue 1.06b/1.12b)
GMI: 1.51 (GM 62.87% / 41.67%)
AQI: 1.06 (AQ_t 0.87 / AQ_t-1 0.83)
SGI: 0.95 (Revenue 1.06b / 1.12b)
TATA: 0.00 (NI 738.7m - CFO 708.3m) / TA 25.3b)
Beneish M = -2.64 (Cap -4..+1) = A
What is the price of COV shares?

As of July 02, 2026, the stock is trading at EUR 53.60 with a total of 253,166 shares traded. Over the past week, the price has changed by -1.77%, over one month by -4.26%, over three months by -1.03% and over the past year by +1.24%.

Current recommended Stop Loss: 51.90 (which is 3.2% or 1.7 ATR below the current price).

Is COV a buy, sell or hold?

Covivio has no consensus analysts rating.

Covivio (COV) - Fundamental Data Overview as of 28 June 2026
Market Cap USD = 6.97b (6.11b EUR * 1.1412 EUR.USD)
P/E Trailing = 8.3183
P/E Forward = 10.9409
P/S = 5.3305
P/B = 0.7009
P/EG = 24.6239
Revenue TTM = 1.06b EUR
EBIT TTM = 1.30b EUR
EBITDA TTM = 1.45b EUR
Long Term Debt = 8.66b EUR (from longTermDebt, last quarter)
Short Term Debt = 1.98b EUR (from shortTermDebt, last quarter)
Debt = 11.2b EUR (from shortLongTermDebtTotal, last quarter) + Leases 304.4m
Net Debt = 10.0b EUR (calculated: Debt 11.2b - CCE 1.21b)
Enterprise Value = 16.1b EUR (6.11b + Debt 11.2b - CCE 1.21b)
Interest Coverage Ratio = 3.85 (Ebit TTM 1.30b / Interest Expense TTM 338.1m)
EV/FCF = 125.4x (Enterprise Value 16.1b / FCF TTM 128.7m)
FCF Yield = 0.80% (FCF TTM 128.7m / Enterprise Value 16.1b)
FCF Margin = 12.10% (FCF TTM 128.7m / Revenue TTM 1.06b)
Net Margin = 69.47% (Net Income TTM 738.7m / Revenue TTM 1.06b)
Gross Margin = 41.67% ((Revenue TTM 1.06b - Cost of Revenue TTM 620.2m) / Revenue TTM)
Gross Margin QoQ = -2.96% (prev 62.50%)
Tobins Q-Ratio = 0.64 (Enterprise Value 16.1b / Total Assets 25.3b)
Interest Expense / Debt = 3.01% (Interest Expense 338.1m / Debt 11.2b)
Taxrate = 25.0% (non-US conservative default 25%)
NOPAT = 977.1m (EBIT 1.30b * (1 - 25.00%))
Current Ratio = 0.64 (Total Current Assets 1.21b / Total Current Liabilities 1.90b)
Debt / Equity = 1.30 (Debt 11.2b / totalStockholderEquity, last quarter 8.61b)
Debt / EBITDA = 6.93 (Net Debt 10.0b / EBITDA 1.45b)
Debt / FCF = 77.96 (Net Debt 10.0b / FCF TTM 128.7m)
Total Stockholder Equity = 8.30b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.94% (Net Income 738.7m / Total Assets 25.3b)
RoE = 8.90% (Net Income TTM 738.7m / Total Stockholder Equity 8.30b)
RoCE = 7.68% (EBIT 1.30b / Capital Employed (Equity 8.30b + L.T.Debt 8.66b))
RoIC = 3.85% (NOPAT 977.1m / Invested Capital 25.4b)
WACC = 3.78% (E(6.11b)/V(17.3b) * Re(6.59%) + D(11.2b)/V(17.3b) * Rd(3.01%) * (1-Tc(0.25)))
Discount Rate = 6.59% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 82.22 | Cagr: 7.44%
[DCF] Terminal Value 73.10% ; FCFF base≈211.6m ; Y1≈185.6m ; Y5≈150.0m
 [DCF] Fair Price = N/A (negative equity: EV 2.41b - Net Debt 10.0b = -7.63b; debt exceeds intrinsic value)
 EPS Correlation: 39.99 | EPS CAGR: 38.06% | SUE: N/A | # QB: 0
Revenue Correlation: 37.04 | Revenue CAGR: 6.57% | SUE: 0.21 | # QB: 0
EPS current Year (2026-12-31): EPS=4.94 | Chg30d=-0.03% | Revisions=N/A | GrowthEPS=+8.1% | GrowthRev=+45.0%
EPS next Year (2027-12-31): EPS=5.04 | Chg30d=-0.20% | Revisions=N/A | GrowthEPS=+2.1% | GrowthRev=+18.2%